Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Behavioral: Nurse-led intervention
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06572293
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
Phase 2
Not yet recruiting
- Conditions
- Liver Metastases of Colorectal Cancer
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06490913
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: sintilimab，programmed death 1 monoclonal antibody
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06468670
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: chemoradiotherapy （CRT）+sintilimab 1Drug: CRT+sintilimab 2
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06468644
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06463834
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer
Phase 2
Recruiting
- Conditions
- Cervical Cancer Recurrent
- Interventions
- Drug: AK104Drug: Recombinant Human Adenovirus 5 Injection
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06455046
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06455072
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI
Phase 2
Not yet recruiting
- Conditions
- Leptomeningeal Metastasis
- Interventions
- Drug: Double Dose of Third-generation EGFR-TKIDrug: Intrathecal Pemetrexed
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT06441045
- Locations
- 🇨🇳
Gen Lin, Fuzhou, Fujian, China
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
Phase 2
Not yet recruiting
- Conditions
- Immunotherapy Gastroesophageal Junction
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06396585
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
A Phase II Multicenter Clinical Trial of Modified Short-course Radiotherapy Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
Phase 2
Recruiting
- Conditions
- Mid-low Rectal Cancer
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT06333769
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath